Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Retained Earnings (2016 - 2026)

Myriad Genetics has reported Retained Earnings over the past 16 years, most recently at $800000.0 for Q4 2025.

  • Quarterly Retained Earnings rose 200.0% to $800000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $800000.0 through Dec 2025, up 200.0% year-over-year, with the annual reading at $800000.0 for FY2025, 200.0% up from the prior year.
  • Retained Earnings was $800000.0 for Q4 2025 at Myriad Genetics, up from -$100000.0 in the prior quarter.
  • Over five years, Retained Earnings peaked at $800000.0 in Q4 2025 and troughed at -$756.9 million in Q1 2025.
  • The 5-year median for Retained Earnings is -$141.2 million (2021), against an average of -$259.5 million.
  • Year-over-year, Retained Earnings tumbled 8758.11% in 2024 and then skyrocketed 200.0% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$5.1 million in 2021, then plummeted by 7080.39% to -$366.2 million in 2022, then skyrocketed by 98.99% to -$3.7 million in 2023, then skyrocketed by 78.38% to -$800000.0 in 2024, then skyrocketed by 200.0% to $800000.0 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Retained Earnings are $800000.0 (Q4 2025), -$100000.0 (Q3 2025), and -$100000.0 (Q2 2025).